People who interact with chatbots for emotional support or other personal reasons are likelier to report symptoms of depression or anxiety, a new study finds. The researchers from Mass General Brigham ...

A deck brush can be a good tool for the right task. Just ask Veronika, the Brown Swiss cow. Veronika uses both ends of a deck brush to scratch various parts of her body, researchers report January 19 ...

How does a cow scratch an itch on its back? An Austrian cow named Veronika has a solution that could change how we view livestock. For the past decade, Veronika has been observed by her owner ...

Using evolocumab (Repatha; Amgen) to treat stable patients with atherosclerotic cardiovascular disease (ASCVD) and obesity results in a larger decrease in major adverse cardiovascular events than it ...

Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of ...

To better understand which social media platforms Americans use, Pew Research Center surveyed 5,022 U.S. adults from Feb. 5 to June 18, 2025. SSRS conducted this National Public Opinion Reference ...

Nov 8 (Reuters) - Adding Amgen's (AMGN.O), opens new tab cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An Amgen sign is seen at the company's headquarters in Thousand Oaks, California, U.S., November 6, 2019.

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A cholesterol-lowering injection ...

Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that ...

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...